2012-11-09 08:32:16 -

· Laquinimod - Teva to initiate a new Phase III study in the US at year-end
                   - milestone payment of USD 5 M received following a
submitted
application for regulatory approval in Europe
                   - Crohn's Phase II data presented at the UEGW
conference

· TASQ        - biomarker data presented at the ESMO conference
                   - Ipsen to initiate two new clinical Phase II studies:
maintenance therapy for prostate cancer and a study of other types of cancer

· ANYARA   - Phase III study results to be presented Q1 2013

· 57-57        - clinical trial of systemic sclerosis/scleroderma is in progress

· ISI            - project proceeding as planned

· Net sales:  SEK 136.4 M (231.3)

· Operating loss: SEK 168.7 M (loss 6.2)

· Loss after tax: SEK 175.1 M (loss: 1.3)

· Loss per share for the period: SEK 2.54 (loss: 0.02)


For further   information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

This report is also available at www.activebiotech.com


Active Biotech AB Interim report January - September 2012: 
 hugin.info/1002/R/1656396/535516.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Active Biotech via Thomson Reuters ONE
[HUG#1656396]